EFR3A

Across TCGA pan-cancer cohorts, EFR3A Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EFR3A data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher EFR3A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EFR3A expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCS, UCEC, and COAD are the cancer types where EFR3A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.001	0.690	<.001	36	view →
UCEC	DFS	Median	All	0.946	0.603	.002	16	view →
COAD	OS	Median	All	0.570	0.873	.002	10	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	10	view →
STAD	DFS	Median	All	1.000	0.388	.029	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	OS	Median	All	0.003	0.819	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EFR3A–UCS (OS)

Open the UCS breakdown →